The symposium honors the life and achievements of Michael J. Weber, PhD, a renowned scientist, professor, and former director of the UVA Cancer Center who joined the university’s School of Medicine faculty in 1983 and helped establish the Cancer Center a year later. Weber led the center from 2000 to 2013, a period during which it grew into a hub for both patients and researchers through compassionate medical care, expanded clinical trials, and innovative basic and translational research. Under his leadership, the center earned designation as a National Cancer Institute-designated Cancer Center, and it subsequently achieved Comprehensive Cancer Center status under the current director, Thomas P. Loughran Jr., MD. Weber’s own laboratory career left an indelible mark on cancer biology, particularly through his contributions to understanding how cellular signaling pathways drive malignancy and how those pathways can be exploited therapeutically.

Weber’s scientific legacy is anchored in his work on cell signaling and its exploitation for the treatment of prostate and bladder cancer, melanoma, and leukemias. He was a major contributor to the discovery and analysis of the MAP Kinase pathway, a signaling cascade that functions as a key regulator of cell growth and proliferation and that has become one of the most important drug targets in oncology. The MAPK pathway, which transmits signals from cell surface receptors through a chain of protein kinases to the nucleus, is aberrantly activated in a large fraction of human cancers, and drugs designed to block components of this cascade, including BRAF and MEK inhibitors, have transformed outcomes for patients with melanoma and other hard-to-treat tumors. Weber’s later research turned to compensatory survival signaling in chronic lymphocytic leukemia and mantle cell lymphoma, probing how cancer cells reroute their internal communication networks to evade targeted therapies, a phenomenon that remains a central obstacle in drug development. At one point, he ranked among the top one percent of scientists cited in molecular biology, genetics, and biochemistry research, a measure of how deeply his work shaped the field.

This year’s symposium theme, cancer metastasis, reflects both the complexity of the problem and the breadth of expertise now brought to bear on it. Metastasis is not a single event but a multi-step process: tumor cells must invade surrounding tissue, enter circulation, survive the stresses of travel, extravasate into distant organs, and adapt to unfamiliar microenvironments that may initially be hostile to their survival. Each step imposes a bottleneck, and only a tiny fraction of disseminating cells succeeds in forming clinically significant metastases. Yet those that do are responsible for the vast majority of cancer mortality, which is why metastatic disease is significantly more challenging to treat than localized tumors. Loughran emphasized that the program spans the full spectrum of this challenge. “Metastasis is an inherently complex area of cancer research and care, and this year’s presenters cover its full spectrum, from genetics to treatment considerations like survivors’ quality of life,” he said. “That connection between discovery and compassion was a signature of Mike’s career, so the program is a fitting tribute to his memory and his legacy at the Cancer Center.”

The lineup of scheduled presenters reads as a cross-section of the most active frontiers in metastasis research. Among them is Carey K. Anders, MD, Chief of Medical Oncology at the Duke University School of Medicine and Medical Director of the Brain and Spine Metastasis Program at Duke Cancer Center. Anders is a clinician-scientist specializing in breast cancer and its spread to the central nervous system, a complication that has become increasingly prominent as systemic therapies extend the lives of patients with metastatic breast cancer while struggling to penetrate the protective barrier surrounding the brain. Her work addresses one of the most clinically urgent questions in the field: how to deliver effective treatment to tumor cells that have colonized the brain and spinal cord, sanctuaries where many drugs fail to reach therapeutic concentrations.

Joining her is Adrienne Boire, MD, PhD, Scientific Director of the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center at Memorial Sloan Kettering Cancer Center. Boire, also a physician-scientist, is an expert in metastases to the brain and in leptomeningeal disease, a devastating condition in which cancer cells spread into the cerebrospinal fluid and the membranes that envelop the brain and spinal cord. Her research examines the tumor ecosystem within the central nervous system, exploring how metastatic cells scavenge nutrients and remodel their surroundings in the confined and immunologically distinctive environment of the nervous system. This ecosystem perspective, treating metastasis as a dialogue between tumor cells and the host tissue rather than a one-way invasion, has emerged as one of the most influential conceptual shifts in cancer biology over the past decade.

The symposium will also hear from Yibin Kang, PhD, the Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University and Associate Director at the Rutgers Cancer Institute of New Jersey. Kang applies molecular biology, genomics, and computational biology approaches to understand the molecular basis of metastasis, dissecting the genetic programs that allow tumor cells to break away, survive in circulation, and colonize bone and other organs. His integrative approach, combining high-throughput genomic data with mechanistic laboratory studies, exemplifies how modern metastasis research increasingly relies on computational tools to identify the sparse population of cells within a tumor that carry metastatic potential, and to pinpoint the vulnerabilities those cells expose once they settle in new tissue.

Population-level context will come from Ahmedin Jemal, DVM, PhD, Senior Vice President of Surveillance, Prevention and Health Services Research at the American Cancer Society. Jemal is a leading cancer epidemiologist and an expert in population-level trends, and his participation underscores that metastasis is not only a laboratory puzzle but a public health problem. Epidemiological surveillance determines how many patients are diagnosed with metastatic disease, how those numbers shift across age groups, races, and geographies, and how advances in early detection and treatment alter the proportion of cancers caught before they spread. Such data are essential for prioritizing research investment and for evaluating whether new therapies are actually changing survival curves for patients with advanced disease.

Rounding out the program is Danny R. Welch, PhD, Professor of Cancer Biology and Director of the National Foundation for Cancer Research Center for Metastasis Research at Kansas University. Welch discovered multiple genes that inhibit cancer metastasis, a class of suppressor genes that, when functional, prevent disseminated tumor cells from completing the metastatic process. The existence of metastasis suppressors reveals that spreading is not an inevitable consequence of malignancy; rather, it depends on the loss of specific cellular controls. Understanding how these suppressor genes operate, and why they fail, offers a fundamentally different therapeutic strategy from conventional cytotoxic chemotherapy: instead of killing cancer cells directly, the goal would be to restore their dormancy or block their colonization of distant organs, converting aggressive metastatic disease into a manageable chronic condition.

The Weber Symposium will be held from 8 a.m. to 2:15 p.m. on Oct. 2 in the UVA School of Medicine’s Pinn Hall Auditorium, located at 1102 Lane Road. Registration is free and includes breakfast and lunch, and attendees may participate in person or virtually, with registration and additional information available through the UVA Cancer Center’s website. For a research community that has spent decades chipping away at the problem of cancer’s spread, the gathering represents more than an annual tradition; it is a convergence of genetics, molecular biology, epidemiology, and clinical care in the spirit of the scientist it commemorates. In bringing together experts who study metastasis at every scale, from single signaling molecules to national survival statistics, UVA is continuing the dual commitment that defined Weber’s career: rigorous discovery in the laboratory and compassionate attention to the patients whose lives depend on it.

Subject of Research: The sixth-annual Michael J. Weber Symposium at the UVA Comprehensive Cancer Center on cancer metastasis research and care

Article Title: UVA Weber Symposium to explore latest metastasis research, care advances

Article References: UVA Weber Symposium to explore latest metastasis research, care advances. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cancer metastasis, Michael J. Weber Symposium, UVA Comprehensive Cancer Center, MAP Kinase pathway, brain metastases, metastasis suppressor genes, breast cancer, cancer epidemiology, tumor microenvironment, clinical oncology, cell signaling, leptomeningeal disease